Skip to main content
OpenTrials
Completed

NCT Number: NCT00228046

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (ADHD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Long Island Jewish Medical Center / Schneider Children's Hospital, New Hyde Park, New York, United States

Loading trial locations.

About this study

ADHD is one of the most common childhood mental disorders. It often causes impaired functioning in multiple areas, including home, school, and peer relationships. Additionally, children with ADHD often develop aggressive behavior, which is not usually adequately suppressed by standard stimulant treatments for ADHD. In order to address this problem, many physicians prescribe multiple medications at once. There is no clinical evidence, however, proving that this method is safe and effective. This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with ADHD.

Participants in this double blind study will first receive open label stimulant treatment for ADHD and a comorbid disruptive behavior disorder. Participants whose aggressive behavior subsides with stimulant treatment alone will not proceed into the next phase of the study. Participants whose ADHD symptoms lessen from the treatment but whose aggressive behavior persists will be randomly assigned to receive either divalproex sodium or placebo in addition to their stimulant treatment for 8 weeks. Study visits will be held weekly for 11 to 16 weeks. At these visits, aggression levels and medication side effects will be assessed. Families will also meet with the researchers to discuss the child's progress, and attend behavioral counseling with a therapist. Participants who did not continue into the second phase of the study will be asked to return to the study site for a follow-up visit 8 weeks following the end of the first phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of ADHD
  • Diagnosis of opposition defiant disorder or conduct disorder
  • Score that exceeds the study threshhold on the standardized scale of aggressive behavior

Exclusion criteria

  • Current psychosis
  • Current major depression
  • Current pervasive developmental disorder
  • Current obsessive compulsive disorder
  • Any other anxiety disorder as primary diagnosis
  • Mental retardation

Treatment and study plan

Divalproex Sodium

Drug

Methylphenidate

Drug

Dextroamphetamine

Drug

Mixed Amphetamine Salts

Drug

Family Counseling

Behavioral

Behavior Management Training with Parents

Behavioral

Primary outcomes

  1. Aggression (Measured by the Overt Aggression Scale after 8 weeks of treatment)

  2. Improvement of ADHD symptoms (Measured by the Clinical Global Improvement Scale and ADHD Rating Scale after 8 weeks of treatment)

Sponsors and collaborators

Lead sponsor

Stony Brook University

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder

Important dates

Study start
2004
Primary completion
2007
Study completion
2007
First posted
Sep 28, 2005
Registry last updated
Oct 31, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.